Claim Missing Document
Check
Articles

Found 4 Documents
Search

Predictive Accuracy of the Placenta Accreta Index (PAI) for Histopathological Severity in Placenta Accreta Spectrum Disorders: A Prospective Cohort Study Nola Yolanda; Donel S
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 7 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i7.1318

Abstract

Background: Placenta accreta spectrum disorder (PASD) represents a range of conditions characterized by abnormal placental adherence and invasion into the uterine wall, posing significant risks of maternal morbidity and mortality, primarily due to severe hemorrhage. The incidence has risen, largely attributed to increasing rates of cesarean deliveries. Prenatal diagnosis is crucial for optimal management. The Placenta Accreta Index (PAI), an ultrasound-based scoring system, was developed to aid in prenatal risk assessment. This study aimed to evaluate the predictive accuracy and correlation of PAI scores with final histopathological findings in patients with suspected PASD at a tertiary hospital in Riau, Indonesia. Methods: A descriptive-analytical study with prospective data collection was conducted over six months (July-December 2024) at Arifin Achmad Regional General Hospital Pekanbaru. The study included 29 pregnant women diagnosed with placenta previa totalis and suspected PASD based on clinical and initial ultrasound findings. Patients underwent transabdominal Doppler ultrasonography between 32-34 weeks of gestation to calculate the PAI score. Following delivery (primarily via cesarean hysterectomy), placental and uterine specimens underwent histopathological examination to determine the definitive PASD classification (accreta, increta, percreta). Correlation between PAI scores and pathological severity was assessed using the Spearman correlation test. Logistic regression was used to evaluate PAI as a predictor of pathological outcomes. Sensitivity and specificity were calculated using a PAI cut-off score of ≥6. Statistical significance was set at p < 0.05. Results: Of the 29 participants, the mean age was 32.83 ± 2.82 years, the mean parity was 3.21 ± 1.05, and a mean number of prior cesarean sections was 1.72 ± 0.70. Histopathology confirmed PASD in all cases: 23 (79.3%) were placenta accreta, 5 (17.2%) were placenta increta, and 1 (3.5%) was placenta percreta. A statistically significant positive correlation was found between PAI score and histopathological severity (Spearman's R = 0.512, p = 0.012). Logistic regression confirmed PAI score as a significant predictor of pathological outcome (β = 3.64, 95% CI 1.301–5.982, p = 0.003). Using a cut-off score of ≥6, PAI demonstrated a sensitivity of 88.6% and specificity of 83.3% for predicting PASD based on the abstract data. Conclusion: The Placenta Accreta Index (PAI) demonstrated a significant positive correlation with the histopathological severity of Placenta Accreta Spectrum Disorders. PAI serves as a valuable and accurate predictive tool for assessing the degree of placental invasion prenatally. Its use can significantly aid clinicians in risk stratification, surgical planning, and optimizing obstetric management to improve maternal outcomes in this high-risk population.
Predictive Accuracy of the Placenta Accreta Index (PAI) for Histopathological Severity in Placenta Accreta Spectrum Disorders: A Prospective Cohort Study Nola Yolanda; Donel S
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 7 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i7.1318

Abstract

Background: Placenta accreta spectrum disorder (PASD) represents a range of conditions characterized by abnormal placental adherence and invasion into the uterine wall, posing significant risks of maternal morbidity and mortality, primarily due to severe hemorrhage. The incidence has risen, largely attributed to increasing rates of cesarean deliveries. Prenatal diagnosis is crucial for optimal management. The Placenta Accreta Index (PAI), an ultrasound-based scoring system, was developed to aid in prenatal risk assessment. This study aimed to evaluate the predictive accuracy and correlation of PAI scores with final histopathological findings in patients with suspected PASD at a tertiary hospital in Riau, Indonesia. Methods: A descriptive-analytical study with prospective data collection was conducted over six months (July-December 2024) at Arifin Achmad Regional General Hospital Pekanbaru. The study included 29 pregnant women diagnosed with placenta previa totalis and suspected PASD based on clinical and initial ultrasound findings. Patients underwent transabdominal Doppler ultrasonography between 32-34 weeks of gestation to calculate the PAI score. Following delivery (primarily via cesarean hysterectomy), placental and uterine specimens underwent histopathological examination to determine the definitive PASD classification (accreta, increta, percreta). Correlation between PAI scores and pathological severity was assessed using the Spearman correlation test. Logistic regression was used to evaluate PAI as a predictor of pathological outcomes. Sensitivity and specificity were calculated using a PAI cut-off score of ≥6. Statistical significance was set at p < 0.05. Results: Of the 29 participants, the mean age was 32.83 ± 2.82 years, the mean parity was 3.21 ± 1.05, and a mean number of prior cesarean sections was 1.72 ± 0.70. Histopathology confirmed PASD in all cases: 23 (79.3%) were placenta accreta, 5 (17.2%) were placenta increta, and 1 (3.5%) was placenta percreta. A statistically significant positive correlation was found between PAI score and histopathological severity (Spearman's R = 0.512, p = 0.012). Logistic regression confirmed PAI score as a significant predictor of pathological outcome (β = 3.64, 95% CI 1.301–5.982, p = 0.003). Using a cut-off score of ≥6, PAI demonstrated a sensitivity of 88.6% and specificity of 83.3% for predicting PASD based on the abstract data. Conclusion: The Placenta Accreta Index (PAI) demonstrated a significant positive correlation with the histopathological severity of Placenta Accreta Spectrum Disorders. PAI serves as a valuable and accurate predictive tool for assessing the degree of placental invasion prenatally. Its use can significantly aid clinicians in risk stratification, surgical planning, and optimizing obstetric management to improve maternal outcomes in this high-risk population.
Adjunctive Vaginal Probiotic Therapy for Preterm Premature Rupture of Membranes: A Systematic Review and Meta-Analysis of Latency Period, Maternal Infection, and Neonatal Morbidity Vani Ardiani; Donel S; Maya Savira; Zulmaeta
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 10 No. 1 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v10i1.1484

Abstract

Background: Preterm premature rupture of membranes (PPROM) significantly drives preterm birth rates and consequent neonatal morbidity and mortality. While standard antibiotic therapy aims to prolong pregnancy latency, it concurrently disrupts the protective vaginal microbiota. Adjunctive vaginal probiotics have been investigated as a means to restore beneficial flora, potentially mitigating ascending infection and improving perinatal outcomes. This study systematically synthesized the current randomized trial evidence regarding this adjunctive therapeutic strategy. Methods: We performed a systematic review and meta-analysis following PRISMA guidelines. PubMed, EMBASE, and CENTRAL databases were searched (2014–October 2025) for randomized controlled trials (RCTs) comparing adjunctive vaginal probiotics plus antibiotics versus antibiotics (alone or with placebo) in singleton pregnancies complicated by PPROM between 24+0 and 34+0 weeks’ gestation. Primary outcomes included the latency period (days) and maternal chorioamnionitis or infectious morbidity. Key secondary outcomes were neonatal intensive care unit (NICU) admission, neonatal sepsis, and neonatal mortality. Data were pooled using a random-effects model, calculating Mean Differences (MD) or Risk Ratios (RR) with 95% Confidence Intervals (CI). Risk of bias was assessed using the Cochrane RoB 2 tool. Results: Three RCTs, encompassing 330 participants, met the inclusion criteria. Significant methodological limitations, including high risk of bias and critical baseline confounding by gestational age in the largest trial, were identified across the included studies. A sensitivity analysis addressing high heterogeneity (I²=98%) for latency (excluding one retrospective study; n=290) indicated a modest but statistically significant prolongation associated with probiotics (MD 2.98 days; 95% CI 1.80–4.16; p<0.0001; I²=0%). Probiotic use was linked to a significantly lower risk of maternal infection (RR 0.43; 95% CI 0.24–0.77; p=0.005; I²=0%; n=270). Statistically significant reductions were also observed for NICU admission (RR 0.59; 95% CI 0.46–0.75; p<0.0001; I²=55%; n=330) and neonatal mortality (RR 0.38; 95% CI 0.18–0.81; p=0.01; I²=0%; n=270), although these estimates are likely inflated due to baseline confounding. Conclusion: This meta-analysis suggests adjunctive vaginal probiotics may offer benefits in PPROM management by modestly prolonging latency and significantly reducing maternal infectious morbidity. While substantial reductions in NICU admission and neonatal mortality were observed, these findings must be interpreted with extreme caution due to the limited quantity and low quality of the primary evidence, particularly the high risk of bias and confounding. Definitive conclusions cannot be drawn, and routine clinical adoption is not supported by current evidence. High-quality, large-scale RCTs are imperative.
Adjunctive Vaginal Probiotic Therapy for Preterm Premature Rupture of Membranes: A Systematic Review and Meta-Analysis of Latency Period, Maternal Infection, and Neonatal Morbidity Vani Ardiani; Donel S; Maya Savira; Zulmaeta
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 10 No. 1 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v10i1.1484

Abstract

Background: Preterm premature rupture of membranes (PPROM) significantly drives preterm birth rates and consequent neonatal morbidity and mortality. While standard antibiotic therapy aims to prolong pregnancy latency, it concurrently disrupts the protective vaginal microbiota. Adjunctive vaginal probiotics have been investigated as a means to restore beneficial flora, potentially mitigating ascending infection and improving perinatal outcomes. This study systematically synthesized the current randomized trial evidence regarding this adjunctive therapeutic strategy. Methods: We performed a systematic review and meta-analysis following PRISMA guidelines. PubMed, EMBASE, and CENTRAL databases were searched (2014–October 2025) for randomized controlled trials (RCTs) comparing adjunctive vaginal probiotics plus antibiotics versus antibiotics (alone or with placebo) in singleton pregnancies complicated by PPROM between 24+0 and 34+0 weeks’ gestation. Primary outcomes included the latency period (days) and maternal chorioamnionitis or infectious morbidity. Key secondary outcomes were neonatal intensive care unit (NICU) admission, neonatal sepsis, and neonatal mortality. Data were pooled using a random-effects model, calculating Mean Differences (MD) or Risk Ratios (RR) with 95% Confidence Intervals (CI). Risk of bias was assessed using the Cochrane RoB 2 tool. Results: Three RCTs, encompassing 330 participants, met the inclusion criteria. Significant methodological limitations, including high risk of bias and critical baseline confounding by gestational age in the largest trial, were identified across the included studies. A sensitivity analysis addressing high heterogeneity (I²=98%) for latency (excluding one retrospective study; n=290) indicated a modest but statistically significant prolongation associated with probiotics (MD 2.98 days; 95% CI 1.80–4.16; p<0.0001; I²=0%). Probiotic use was linked to a significantly lower risk of maternal infection (RR 0.43; 95% CI 0.24–0.77; p=0.005; I²=0%; n=270). Statistically significant reductions were also observed for NICU admission (RR 0.59; 95% CI 0.46–0.75; p<0.0001; I²=55%; n=330) and neonatal mortality (RR 0.38; 95% CI 0.18–0.81; p=0.01; I²=0%; n=270), although these estimates are likely inflated due to baseline confounding. Conclusion: This meta-analysis suggests adjunctive vaginal probiotics may offer benefits in PPROM management by modestly prolonging latency and significantly reducing maternal infectious morbidity. While substantial reductions in NICU admission and neonatal mortality were observed, these findings must be interpreted with extreme caution due to the limited quantity and low quality of the primary evidence, particularly the high risk of bias and confounding. Definitive conclusions cannot be drawn, and routine clinical adoption is not supported by current evidence. High-quality, large-scale RCTs are imperative.